{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:08:13Z","timestamp":1769220493275,"version":"3.49.0"},"reference-count":35,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Travel-related burdens are an ongoing issue for cancer and other specialty care patients. To address these issues, the Veterans Health Administration (VA) National Oncology Program sponsors the Close to Me (CTM) care model to facilitate novel care delivery strategies throughout the VA system. The VA Ann Arbor Healthcare System (VAAAHS) Hematology-Oncology Clinic implemented CTM, using local VA clinics and home-based therapies to reduce travel burdens for Veterans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Veterans eligible for CTM included those receiving infusion treatments through the VAAAHS who lived near a VA community-based outpatient clinic (CBOC) regardless of primary specialty, and Veterans with multiple myeloma receiving bortezomib subcutaneously. After enrollment, Veterans received their infusion therapies at a CBOC, administered by traveling VAAAHS infusion nurses. Veterans with multiple myeloma self-administered bortezomib at home under direct observation of an infusion nurse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>From October 2024 to June 2025, we enrolled 102 patients in the CTM program. Patients saved 21,840 total travel miles, for an estimated $8,954 of travel-related costs saved by patients receiving care at a local clinic or at home. A total of 261 treatment visits were completed, with an estimated $403,432 of potential drug cost-savings on the basis of VA versus Medicare Average Sales Pricing File data. There were no serious adverse events related to patients receiving therapy locally or at home, with overall 98.5% treatment adherence. Patient satisfaction was high, with most patients rating their experience as excellent and reporting that they would recommend this service to others.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>The VAAAHS CTM program demonstrates the safety and feasibility of a local clinic and home-based infusion program through the VA, resulting in significant travel and cost-savings for patients. Our experience addresses issues related to the delivery of cancer care in both VA and non-VA settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-01082","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:59:12Z","timestamp":1769201952000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Implementation and Evaluation of Close to Me, a Novel Outpatient Clinic and Home-Based Infusion Therapy Program Through the Veterans Health Administration"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0988-766X","authenticated-orcid":true,"given":"Jason C.","family":"Chen","sequence":"first","affiliation":[{"name":"Hematology\/Oncology, LTC Charles S. Kettles VA Medical Center, Ann Arbor, MI"},{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Shields","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Bredin","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, LTC Charles S. Kettles VA Medical Center, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Carelli","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, LTC Charles S. Kettles VA Medical Center, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3975-7292","authenticated-orcid":true,"given":"Brian","family":"Bazzell","sequence":"additional","affiliation":[{"name":"Corewell Health, Blood and Marrow Transplant and Cellular Therapy, Grand Rapids, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal","family":"Higashimoto","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, LTC Charles S. Kettles VA Medical Center, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9947-7156","authenticated-orcid":true,"given":"Christine","family":"Veenstra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4846-7596","authenticated-orcid":true,"given":"Alice","family":"Cusick","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, LTC Charles S. Kettles VA Medical Center, Ann Arbor, MI"},{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4101-4292","authenticated-orcid":true,"given":"Vida","family":"Passero","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"e_1_3_8_2_2","volume-title":"VA.gov | Veterans Affairs","author":"Administration VH","unstructured":"Administration VH: VA.gov | Veterans Affairs. https:\/\/www.va.gov\/health\/"},{"key":"e_1_3_8_3_2","volume-title":"Rural Veterans and Access to Healthcare Overview - Rural Health Information Hub","unstructured":"Rural Veterans and Access to Healthcare Overview - Rural Health Information Hub. https:\/\/www.ruralhealthinfo.org\/topics\/returning-soldier-and-veteran-health"},{"key":"e_1_3_8_4_2","volume-title":"Rural Project Summary: I-REACH (Improving Rural Enrollment, Access, and Healthcare in Rural Veterans)\u2014Rural Health Information Hub","unstructured":"Rural Project Summary: I-REACH (Improving Rural Enrollment, Access, and Healthcare in Rural Veterans)\u2014Rural Health Information Hub. https:\/\/www.ruralhealthinfo.org\/project-examples\/1127"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00890"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.07.006"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27935"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/gin2.70030"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00175"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272076"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23229"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-8282-z"},{"key":"e_1_3_8_13_2","volume-title":"Diffusion Marketplace","unstructured":"Diffusion Marketplace. https:\/\/marketplace.va.gov\/innovations\/close-to-me-infusion-service"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1519"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.2024.20.10_suppl.111"},{"key":"e_1_3_8_16_2","volume-title":"CBOC Infusion Program | MDedge","author":"Close to Me","unstructured":"Close to Me: CBOC Infusion Program | MDedge. https:\/\/mdedge.com\/fedprac\/article\/257551\/oncology\/close-me-cboc-infusion-program"},{"key":"e_1_3_8_17_2","unstructured":"Antineoplastic therapy administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS standards. Oncol Nurs Forum 2024 https:\/\/www.ons.org\/onf\/51\/3\/antineoplastic-therapy-administration-safety-standards-adult-and-pediatric-oncology-asco"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146605"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136342"},{"key":"e_1_3_8_20_2","volume-title":"Veterans Integrated Services Networks (VISN), Markets, Submarkets, Sectors and Counties by Geographic Location | Department of Veterans Affairs Open Data Portal","unstructured":"Veterans Integrated Services Networks (VISN), Markets, Submarkets, Sectors and Counties by Geographic Location | Department of Veterans Affairs Open Data Portal. https:\/\/www.data.va.gov\/dataset\/Veterans-Integrated-Services-Networks-VISN-Markets\/9hbf-9jzg\/about_data"},{"key":"e_1_3_8_21_2","volume-title":"Reimbursed VA Travel Expenses and Mileage Rate","year":"2025","unstructured":"Reimbursed VA Travel Expenses and Mileage Rate. Veterans Aff, 2025. https:\/\/www.va.gov\/resources\/reimbursed-va-travel-expenses-and-mileage-rate\/"},{"key":"e_1_3_8_22_2","unstructured":"ASP Pricing Files | CMS. https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files"},{"key":"e_1_3_8_23_2","volume-title":"Prescription Drugs: Department of Veterans Affairs Paid About Half as Much as Medicare Part D for Selected Drugs in 2017","author":"Office USGA","unstructured":"Office USGA: Prescription Drugs: Department of Veterans Affairs Paid About Half as Much as Medicare Part D for Selected Drugs in 2017. Washington, DC, U.S. GAO. https:\/\/www.gao.gov\/products\/gao-21-111"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","unstructured":"Friedman DR Elam SL Bloemers S et al: Cancer decentralized clinical trials in the veterans health administration. J Natl Cancer Inst 10.1093\/jnci\/djaf279 [epub ahead of print on September 24 2025]","DOI":"10.1093\/jnci\/djaf279"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-919"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00261"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/17407745221090733"},{"key":"e_1_3_8_28_2","first-page":"248","article-title":"Using health care failure mode and effect analysisTM: The VA National Center for patient safety\u2019s prospective risk analysis system","volume":"28","author":"DeRosier J","year":"2002","unstructured":"DeRosier J, Stalhandske E, Bagian JP, et al: Using health care failure mode and effect analysisTM: The VA National Center for patient safety\u2019s prospective risk analysis system. Jt Comm J Qual Improv 28:248-267, 2002","journal-title":"Jt Comm J Qual Improv"},{"key":"e_1_3_8_29_2","article-title":"Accelerating the delivery of cancer care at home during the Covid-19 pandemic","volume":"1","author":"Laughlin AI","year":"2020","unstructured":"Laughlin AI, Begley M, Delaney T, et al: Accelerating the delivery of cancer care at home during the Covid-19 pandemic. Catal Non-Issue Content 1, 2020. https:\/\/catalyst-nejm-org.proxy.lib.umich.edu\/doi\/full\/10.1056\/CAT.20.0258","journal-title":"Catal Non-Issue Content"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03609"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2000.tb125563.x"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.3310\/hsdr03140"},{"key":"e_1_3_8_33_2","volume-title":"NIOSH List of Hazardous Drugs in Healthcare Settings","year":"2024","unstructured":"NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 https:\/\/www.cdc.gov\/niosh\/docs\/2025-103\/default.html"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2009.09.003"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv563"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00744"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-01082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:59:14Z","timestamp":1769201954000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-01082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":35,"alternative-id":["10.1200\/OP-25-01082"],"URL":"https:\/\/doi.org\/10.1200\/op-25-01082","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2025-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-25-01082"}}